Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Heron Therapeutics, Inc. - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
HRTX
Nasdaq
2830
www.herontx.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Heron Therapeutics, Inc.
Heron Therapeutics, Inc. (NASDAQ:HRTX) is a favorite amongst institutional investors who own 58%
- Jan 21st, 2025 10:17 am
Heron Therapeutics Announces Corporate Headquarters Relocation to Cary, North Carolina
- Dec 23rd, 2024 9:05 pm
Exploring Three High Growth Tech Stocks In The United States
- Dec 11th, 2024 6:03 pm
U.S. District Court Upholds Validity of CINVANTI® Patents
- Dec 3rd, 2024 9:36 pm
Heron Therapeutics Inc (HRTX) Q3 2024 Earnings Call Highlights
- Nov 13th, 2024 7:05 am
Heron Therapeutics (HRTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
- Nov 12th, 2024 3:00 pm
Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates
- Nov 12th, 2024 2:10 pm
Heron Therapeutics: Q3 Earnings Snapshot
- Nov 12th, 2024 1:06 pm
Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial Guidance
- Nov 12th, 2024 12:55 pm
Unveiling Heron Therapeutics (HRTX) Q3 Outlook: Wall Street Estimates for Key Metrics
- Nov 7th, 2024 2:15 pm
Positive Signs As Multiple Insiders Buy Heron Therapeutics Stock
- Nov 5th, 2024 6:26 pm
Heron Therapeutics Announces Appointment of Michael Kaseta to Board of Directors
- Nov 4th, 2024 10:00 pm
Journey Medical (DERM) Soars 7.3%: Is Further Upside Left in the Stock?
- Nov 4th, 2024 12:18 pm
Heron Therapeutics to Report Third Quarter 2024 Financial Results On Tuesday, November 12, 2024
- Oct 29th, 2024 8:05 pm
Heron Therapeutics Reaffirms Availability and Ample Supply of CINVANTI®, SUSTOL®, and APONVIE® as Alternatives During the Potential Shortage of Intravenous Fluids
- Oct 10th, 2024 8:00 pm
Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Path To Profitability
- Oct 2nd, 2024 11:24 am
Heron Therapeutics Announces FDA Approval of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")
- Sep 25th, 2024 12:00 pm
Heron Therapeutics Announces Appointment of Brett Fleshman as Chief Business Officer
- Sep 3rd, 2024 12:00 pm
Heron Therapeutics Second Quarter 2024 Earnings: EPS Misses Expectations
- Aug 8th, 2024 10:48 am
Heron Therapeutics (HRTX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
- Aug 6th, 2024 11:30 pm
Scroll